濮阳惠成 reported revenue of ¥0.76B for the period ended 2026-06-30, +5.7% year on year. Net income was ¥0.06B, a 8.2% net margin on a 21.1% gross margin. The largest revenue line is 顺酐酸酐衍生物 at 72% of the total. Free cash flow for the period was ¥-0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.76B | +5.7% |
| Gross profit | ¥0.16B | — |
| Operating income | ¥0.07B | — |
| Net income | ¥0.06B | -11.9% |
| Gross margin | 21.1% | Net margin 8.2% |
| Revenue Q/Q | +15.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 顺酐酸酐衍生物 | ¥0.55B | 71.6% |
| 功能材料中间体 | ¥0.16B | 20.5% |
| 其他主营业务 | ¥0.06B | 7.6% |
| 其他(补充) | ¥0.00B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.60B | 78.9% |
| R&D | ¥0.05B | 6.4% |
| SG&A | ¥0.03B | 3.5% |
| Tax & other | ¥0.01B | 1.1% |
| Item | Amount |
|---|---|
| Total assets | ¥2.69B |
| Total liabilities | ¥0.26B |
| Shareholders' equity | ¥2.43B |
| Equity / assets | 90.3% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥-0.05B |
| Cash conversion (OCF / net income) | 93% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
万孚生物 ・ 首华燃气 ・ 蓝海华腾 ・ 赛升药业 ・ 东杰智能 ・ 蓝晓科技 ・ 恒锋工具 ・ 光智科技 ・ 华自科技 ・ 通合科技 ・ 华图山鼎 ・ 润欣科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies